Abstract 132P
Background
Oncogenic mutation p53(Y220C) is the ninth most common mutation of the p53 protein. Mutation Y220C creates an expanded surface pocket in the DNA-binding domain of p53, due to which the protein is rapidly denatured under physiological conditions. This also negatively affects the effectiveness of p53-dependent signaling and leads to tumor development. In this work, new indazole derivatives were investigated as modulators of mutant p53 activity. We found that the compounds studied were able to initiate an anti-tumor cellular response by activating mutant p53(Y220C).
Methods
Immunocytochemical analysis (ICC) was performed to test the hypothesis that the mutant protein p53(Y220C) can restore its native-like conformation and get reactivated upon interaction with the compounds. The degree of p53 activation was evaluated, and the protein localization in HUH7 p53(Y220C) human hepatocarcinoma cells was determined upon treatment with indazole derivatives.
Results
During the immunocytochemical analysis, images obtained were analyzed using the ImageJ software, and the values of p53 signal intensity were calculated. We found that in comparison with control untreated cells, in samples treated with indazole derivatives increased in levels of p53 were observed mainly in the nucleus, which indicates its activation.
Conclusions
The results of the immunocytochemical analysis demonstrated that indazole derivatives specifically activate mutant p53(Y220C) protein. The compounds represent a promising basis for the development of selective activators not only for Y220C, but also for other mutant forms of p53. The work was funded by grant from the Russian Science Foundation 22-24-20034 and supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The work was funded by grant from the Russian Science Foundation 22-24-20034 and supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study
Presenter: Christophe Mapendano
Session: Cocktail & Poster Display session
Resources:
Abstract